Anti-KIF13A (Internal Region) Polyclonal Antibody (DPABH-13819) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use

Total Page：16

File Type：pdf, Size：1020Kb

Anti-KIF13A (internal region) polyclonal antibody (DPABH-13819) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Antigen Description Plus end-directed microtubule-dependent motor protein involved in intracellular transport and regulating various processes such as mannose-6-phosphate receptor (M6PR) transport to the plasma membrane, endosomal sorting during melanosome biogenesis and cytokinesis. Mediates the transport of M6PR-containing vesicles from trans-Golgi network to the plasma membrane via direct interaction with the AP-1 complex. During melanosome maturation, required for delivering melanogenic enzymes from recycling endosomes to nascent melanosomes by creating peripheral recycling endosomal subdomains in melanocytes. Also required for the abcission step in cytokinesis: mediates translocation of ZFYVE26, and possibly TTC19, to the midbody during cytokinesis. Specificity Cross reacts with many mammalian proteins due to sequence homology. Immunogen Synthetic peptide within Human KIF13A (internal sequence). The exact sequence is proprietary.Database link: KIF13A Isotype IgG Source/Host Rabbit Species Reactivity Human Purification Protein A purified Conjugate Unconjugated Applications IHC-P, WB Format Liquid Size 100 μg Buffer Constituents: 1.21% Tris, 0.75% Glycine, 2% Sucrose Preservative None Storage Shipped at 4°C. Store at 4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved GENE INFORMATION Gene Name KIF13A kinesin family member 13A [ Homo sapiens ] Official Symbol KIF13A Synonyms KIF13A; kinesin family member 13A; kinesin-like protein KIF13A; bA500C11.2; kinesin-like protein RBKIN; homolog of mouse KIF13A mannose-6-phosphate receptor transporter; RBKIN; FLJ27232; Entrez Gene ID 63971 Protein Refseq NP_001099036 UniProt ID Q9H1H9 Chromosome Location 6p23 Pathway Association of TriC/CCT with target proteins during biosynthesis; Chaperonin-mediated protein folding; Metabolism of proteins; Protein folding; Function ATP binding; microtubule motor activity; nucleotide binding; protein binding; 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 2 © Creative Diagnostics All Rights Reserved.

Copy Link

Recommended publications

The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid
The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome Annette K. Brenner, Elise Aasebø, Maria Hernandez-Valladares, Frode Selheim, Frode Berven, Ida-Sofie Grønningsæter, Sushma Bartaula-Brevik and Øystein Bruserud Supplementary Material S2 of S31 Table S1. Detailed information about the 68 AML patients included in the study. # of blasts Viability Proliferation Cytokine Viable cells Change in ID Gender Age Etiology FAB Cytogenetics Mutations CD34 Colonies (109/L) (%) 48 h (cpm) secretion (106) 5 weeks phenotype 1 M 42 de novo 241 M2 normal Flt3 pos 31.0 3848 low 0.24 7 yes 2 M 82 MF 12.4 M2 t(9;22) wt pos 81.6 74,686 low 1.43 969 yes 3 F 49 CML/relapse 149 M2 complex n.d. pos 26.2 3472 low 0.08 n.d. no 4 M 33 de novo 62.0 M2 normal wt pos 67.5 6206 low 0.08 6.5 no 5 M 71 relapse 91.0 M4 normal NPM1 pos 63.5 21,331 low 0.17 n.d. yes 6 M 83 de novo 109 M1 n.d. wt pos 19.1 8764 low 1.65 693 no 7 F 77 MDS 26.4 M1 normal wt pos 89.4 53,799 high 3.43 2746 no 8 M 46 de novo 26.9 M1 normal NPM1 n.d. n.d. 3472 low 1.56 n.d. no 9 M 68 MF 50.8 M4 normal D835 pos 69.4 1640 low 0.08 n.d.
[Show full text]
Table SI. Genes Upregulated ≥ 2-Fold by MIH 2.4Bl Treatment Affymetrix ID
Table SI. Genes upregulated 2-fold by MIH 2.4Bl treatment Fold UniGene ID Description Affymetrix ID Entrez Gene Change 1558048_x_at 28.84 Hs.551290 231597_x_at 17.02 Hs.720692 238825_at 10.19 93953 Hs.135167 acidic repeat containing (ACRC) 203821_at 9.82 1839 Hs.799 heparin binding EGF like growth factor (HBEGF) 1559509_at 9.41 Hs.656636 202957_at 9.06 3059 Hs.14601 hematopoietic cell-specific Lyn substrate 1 (HCLS1) 202388_at 8.11 5997 Hs.78944 regulator of G-protein signaling 2 (RGS2) 213649_at 7.9 6432 Hs.309090 serine and arginine rich splicing factor 7 (SRSF7) 228262_at 7.83 256714 Hs.127951 MAP7 domain containing 2 (MAP7D2) 38037_at 7.75 1839 Hs.799 heparin binding EGF like growth factor (HBEGF) 224549_x_at 7.6 202672_s_at 7.53 467 Hs.460 activating transcription factor 3 (ATF3) 243581_at 6.94 Hs.659284 239203_at 6.9 286006 Hs.396189 leucine rich single-pass membrane protein 1 (LSMEM1) 210800_at 6.7 1678 translocase of inner mitochondrial membrane 8 homolog A (yeast) (TIMM8A) 238956_at 6.48 1943 Hs.741510 ephrin A2 (EFNA2) 242918_at 6.22 4678 Hs.319334 nuclear autoantigenic sperm protein (NASP) 224254_x_at 6.06 243509_at 6 236832_at 5.89 221442 Hs.374076 adenylate cyclase 10, soluble pseudogene 1 (ADCY10P1) 234562_x_at 5.89 Hs.675414 214093_s_at 5.88 8880 Hs.567380; far upstream element binding protein 1 (FUBP1) Hs.707742 223774_at 5.59 677825 Hs.632377 small nucleolar RNA, H/ACA box 44 (SNORA44) 234723_x_at 5.48 Hs.677287 226419_s_at 5.41 6426 Hs.710026; serine and arginine rich splicing factor 1 (SRSF1) Hs.744140 228967_at 5.37
[Show full text]
Hereditary Spastic Paraplegia: from Genes, Cells and Networks to Novel Pathways for Drug Discovery
brain sciences Review Hereditary Spastic Paraplegia: From Genes, Cells and Networks to Novel Pathways for Drug Discovery Alan Mackay-Sim Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia; a.mackay-sim@griffith.edu.au Abstract: Hereditary spastic paraplegia (HSP) is a diverse group of Mendelian genetic disorders affect- ing the upper motor neurons, specifically degeneration of their distal axons in the corticospinal tract. Currently, there are 80 genes or genomic loci (genomic regions for which the causative gene has not been identified) associated with HSP diagnosis. HSP is therefore genetically very heterogeneous. Finding treatments for the HSPs is a daunting task: a rare disease made rarer by so many causative genes and many potential mutations in those genes in individual patients. Personalized medicine through genetic correction may be possible, but impractical as a generalized treatment strategy. The ideal treatments would be small molecules that are effective for people with different causative mutations. This requires identification of disease-associated cell dysfunctions shared across geno- types despite the large number of HSP genes that suggest a wide diversity of molecular and cellular mechanisms. This review highlights the shared dysfunctional phenotypes in patient-derived cells from patients with different causative mutations and uses bioinformatic analyses of the HSP genes to identify novel cell functions as potential targets for future drug treatments for multiple genotypes. Keywords: neurodegeneration; motor neuron disease; spastic paraplegia; endoplasmic reticulum; Citation: Mackay-Sim, A. Hereditary protein-protein interaction network Spastic Paraplegia: From Genes, Cells and Networks to Novel Pathways for Drug Discovery. Brain Sci. 2021, 11, 403.
[Show full text]
Download Ppis for Each Single Seed, Thus Obtaining Each Seed’S Interactome (Ferrari Et Al., 2018)
bioRxiv preprint doi: https://doi.org/10.1101/2021.01.14.425874; this version posted January 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias Nikoleta Vavouraki1,2, James E. Tomkins1, Eleanna Kara3, Henry Houlden3, John Hardy4, Marcus J. Tindall2,5, Patrick A. Lewis1,4,6, Claudia Manzoni1,7* Author Affiliations 1: Department of Pharmacy, University of Reading, Reading, RG6 6AH, United Kingdom 2: Department of Mathematics and Statistics, University of Reading, Reading, RG6 6AH, United Kingdom 3: Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom 4: Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom 5: Institute of Cardiovascular and Metabolic Research, University of Reading, Reading, RG6 6AS, United Kingdom 6: Department of Comparative Biomedical Sciences, Royal Veterinary College, London, NW1 0TU, United Kingdom 7: School of Pharmacy, University College London, London, WC1N 1AX, United Kingdom *Corresponding author: [email protected] Abstract The Hereditary Spastic Paraplegias are a group of neurodegenerative diseases characterized by spasticity and weakness in the lower body. Despite the identification of causative mutations in over 70 genes, the molecular aetiology remains unclear. Due to the combination of genetic diversity and variable clinical presentation, the Hereditary Spastic Paraplegias are a strong candidate for protein- protein interaction network analysis as a tool to understand disease mechanism(s) and to aid functional stratification of phenotypes.
[Show full text]
Comparative Analysis of the Domestic Cat Genome Reveals Genetic Signatures Underlying Feline Biology and Domestication
Comparative analysis of the domestic cat genome reveals genetic signatures underlying feline biology and domestication Michael J. Montaguea,1, Gang Lib,1, Barbara Gandolfic, Razib Khand, Bronwen L. Akene, Steven M. J. Searlee, Patrick Minxa, LaDeana W. Hilliera, Daniel C. Koboldta, Brian W. Davisb, Carlos A. Driscollf, Christina S. Barrf, Kevin Blackistonef, Javier Quilezg, Belen Lorente-Galdosg, Tomas Marques-Bonetg,h, Can Alkani, Gregg W. C. Thomasj, Matthew W. Hahnj, Marilyn Menotti-Raymondk, Stephen J. O’Brienl,m, Richard K. Wilsona, Leslie A. Lyonsc,2, William J. Murphyb,2, and Wesley C. Warrena,2 aThe Genome Institute, Washington University School of Medicine, St. Louis, MO 63108; bDepartment of Veterinary Integrative Biosciences, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843; cDepartment of Veterinary Medicine & Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65201; dPopulation Health & Reproduction, School of Veterinary Medicine, University of California, Davis, CA 95616; eWellcome Trust Sanger Institute, Hinxton CB10 1SA, United Kingdom; fNational Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20886; gCatalan Institution for Research and Advanced Studies, Institute of Evolutionary Biology, Pompeu Fabra University, 08003 Barcelona, Spain; hCentro de Analisis Genomico 08028, Barcelona, Spain; iDepartment of Computer Engineering, Bilkent University, Ankara 06800, Turkey; jDepartment of Biology, Indiana University, Bloomington,
[Show full text]
Gnomad Lof Supplement
1 gnomAD supplement gnomAD supplement 1 Data processing 4 Alignment and read processing 4 Variant Calling 4 Coverage information 5 Data processing 5 Sample QC 7 Hard filters 7 Supplementary Table 1 | Sample counts before and after hard and release filters 8 Supplementary Table 2 | Counts by data type and hard filter 9 Platform imputation for exomes 9 Supplementary Table 3 | Exome platform assignments 10 Supplementary Table 4 | Confusion matrix for exome samples with Known platform labels 11 Relatedness filters 11 Supplementary Table 5 | Pair counts by degree of relatedness 12 Supplementary Table 6 | Sample counts by relatedness status 13 Population and subpopulation inference 13 Supplementary Figure 1 | Continental ancestry principal components. 14 Supplementary Table 7 | Population and subpopulation counts 16 Population- and platform-specific filters 16 Supplementary Table 8 | Summary of outliers per population and platform grouping 17 Finalizing samples in the gnomAD v2.1 release 18 Supplementary Table 9 | Sample counts by filtering stage 18 Supplementary Table 10 | Sample counts for genomes and exomes in gnomAD subsets 19 Variant QC 20 Hard filters 20 Random Forest model 20 Features 21 Supplementary Table 11 | Features used in final random forest model 21 Training 22 Supplementary Table 12 | Random forest training examples 22 Evaluation and threshold selection 22 Final variant counts 24 Supplementary Table 13 | Variant counts by filtering status 25 Comparison of whole-exome and whole-genome coverage in coding regions 25 Variant annotation 30 Frequency and context annotation 30 2 Functional annotation 31 Supplementary Table 14 | Variants observed by category in 125,748 exomes 32 Supplementary Figure 5 | Percent observed by methylation.
[Show full text]
FYVE-CENT Antibody A
Revision 1 C 0 2 - t FYVE-CENT Antibody a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 2 3 Web: [email protected] 5 www.cellsignal.com 8 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source: UniProt ID: Entrez-Gene Id: WB, IP H Endogenous 285 Rabbit Q68DK2 23503 Product Usage Information Application Dilution Western Blotting 1:1000 Immunoprecipitation 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody. Specificity / Sensitivity FYVE-CENT Antibody recognizes endogenous levels of total FYVE-CENT protein. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu595 of human FYVE-CENT protein. Antibodies are purified by protein A and peptide affinity chromatography. Background FYVE-CENT (ZFYVE26) contains an FYVE zinc finger domain characterized by conserved R(R/RK) and HHCRxCG motifs (1). Phosphatidylinositol 3 phosphate binds to FYVE-CENT via the FYVE domain and this binding is crucial in phosphoinositide (PtdIns3P)-regulated cytokinesis (1-3). Research evidence suggests that during cytokinesis, FYVE-CENT directly interacts with TTC19 and is recruited to the midbody by the kinesin protein KIF13A (4). FYVE-CENT may also be involved in the tumor suppressor function of Beclin-1 (5). Researchers have linked the defects in FYVE-CENT to hereditary spastic paraplegia, a condition characterized by deterioration of the corpus callosum of the brain (6).
[Show full text]
Transposon Mutagenesis Identifies Genetic Drivers of Brafv600e Melanoma
ARTICLES Transposon mutagenesis identifies genetic drivers of BrafV600E melanoma Michael B Mann1,2, Michael A Black3, Devin J Jones1, Jerrold M Ward2,12, Christopher Chin Kuan Yew2,12, Justin Y Newberg1, Adam J Dupuy4, Alistair G Rust5,12, Marcus W Bosenberg6,7, Martin McMahon8,9, Cristin G Print10,11, Neal G Copeland1,2,13 & Nancy A Jenkins1,2,13 Although nearly half of human melanomas harbor oncogenic BRAFV600E mutations, the genetic events that cooperate with these mutations to drive melanogenesis are still largely unknown. Here we show that Sleeping Beauty (SB) transposon-mediated mutagenesis drives melanoma progression in BrafV600E mutant mice and identify 1,232 recurrently mutated candidate cancer genes (CCGs) from 70 SB-driven melanomas. CCGs are enriched in Wnt, PI3K, MAPK and netrin signaling pathway components and are more highly connected to one another than predicted by chance, indicating that SB targets cooperative genetic networks in melanoma. Human orthologs of >500 CCGs are enriched for mutations in human melanoma or showed statistically significant clinical associations between RNA abundance and survival of patients with metastatic melanoma. We also functionally validate CEP350 as a new tumor-suppressor gene in human melanoma. SB mutagenesis has thus helped to catalog the cooperative molecular mechanisms driving BRAFV600E melanoma and discover new genes with potential clinical importance in human melanoma. Substantial sun exposure and numerous genetic factors, including including BrafV600E, recapitulate the genetic and histological hallmarks skin type and family history, are the most important melanoma risk of human melanoma. In these models, increased MEK-ERK signaling factors. Familial melanoma, which accounts for <10% of cases, is asso- initiates clonal expansion of melanocytes, which is limited by oncogene- ciated with mutations in CDKN2A1, MITF2 and POT1 (refs.
[Show full text]
Integrative Functional Analyses of the Neurodegenerative Disease-Associated TECPR2 Gene Reveal Its Diverse Roles
Integrative functional analyses of the neurodegenerative disease-associated TECPR2 gene reveal its diverse roles Ido Shalev Ben-Gurion University of the Negev Judith Somekh University of Haifa Alal Eran ( [email protected] ) Ben-Gurion University of the Negev https://orcid.org/0000-0001-6784-7597 Research article Keywords: Integrative functional analysis, neurodegenerative disorders, autophagy, ribosome, TECPR2 Posted Date: January 30th, 2020 DOI: https://doi.org/10.21203/rs.2.22274/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/23 Abstract Background Loss of tectonin β-propeller repeat-containing 2 (TECPR2) function has been implicated in an array of neurodegenerative disorders, yet its physiological function remains largely unknown. Understanding TECPR2 function is essential for developing much needed precision therapeutics for TECPR2-related diseases. Methods We leveraged the considerable amounts of functional data to obtain a comprehensive perspective of the role of TECPR2 in health and disease. We integrated expression patterns, population variation, phylogenetic proling, protein-protein interactions, and regulatory network data for a minimally biased multimodal functional analysis. Genes and proteins linked to TECPR2 via multiple lines of evidence were subject to functional enrichment analyses to identify molecular mechanisms involving TECPR2. Results TECPR2 was found to be part of a tight neurodevelopmental gene expression program that includes KIF1A, ATXN1, TOM1L2, and FA2H, all implicated in neurological diseases. Functional enrichment analyses of TECPR2-related genes converged on a role in late autophagy and ribosomal processes. Large-scale population variation data demonstrated that this role is nonredundant. Conclusions TECPR2 might serve as an indicator for the energy balance between protein synthesis and autophagy, and a marker for diseases associated with their imbalance, such as Alzheimer’s disease, Huntington’s disease, and various cancers.
[Show full text]
ZFYVE26 (N-20): Sc-79372
SAN TA C RUZ BI OTEC HNOL OG Y, INC . ZFYVE26 (N-20): sc-79372 BACKGROUND PRODUCT Zinc finger proteins contain DNA-binding domains and have a wide variety of Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide functions, most of which encompass some form of transcriptional activation and 0.1% gelatin. or repression. ZFYVE26 (zinc finger, FYVE domain containing 26), also known Blocking peptide available for competition studies, sc-79372 P, (100 µg as SPG15, is a 2,539 amino acid protein that exists as multiple alternatively peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA). spliced isoforms and contains one FYVE-type zinc finger. Expressed at high levels in brain, prostate, lung, testis, retina, bone marrow and adrenal gland, APPLICATIONS ZFYVE26 is thought to interact with phospholipids in the membrane and may be involved in transcriptional regulation events. Defects in the gene encoding ZFYVE26 (N-20) is recommended for detection of ZFYVE26 of mouse, rat ZFYVE26 are the cause of spastic paraplegia autosomal recessive type 15 and human origin by Western Blotting (starting dilution 1:200, dilution range (SPG15), a neurodegenerative disorder that is characterized by difficulty with 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range balance, weakness and stiffness in the legs, muscle spasms, mental retarda - 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range tion, axonal neuropathy and retinal degeneration. 1:30-1:3000). ZFYVE26 (N-20) is also recommended for detection of ZFYVE26 in additional REFERENCES species, including equine, canine, bovine and porcine.
[Show full text]
Genomics of Asthma, Allergy and Chronic Rhinosinusitis
Laulajainen‑Hongisto et al. Clin Transl Allergy (2020) 10:45 https://doi.org/10.1186/s13601‑020‑00347‑6 Clinical and Translational Allergy REVIEW Open Access Genomics of asthma, allergy and chronic rhinosinusitis: novel concepts and relevance in airway mucosa Anu Laulajainen‑Hongisto1,2†, Annina Lyly1,3*† , Tanzeela Hanif4, Kishor Dhaygude4, Matti Kankainen5,6,7, Risto Renkonen4,5, Kati Donner6, Pirkko Mattila4,6, Tuomas Jartti8, Jean Bousquet9,10,11, Paula Kauppi3† and Sanna Toppila‑Salmi3,4† Abstract Genome wide association studies (GWASs) have revealed several airway disease‑associated risk loci. Their role in the onset of asthma, allergic rhinitis (AR) or chronic rhinosinusitis (CRS), however, is not yet fully understood. The aim of this review is to evaluate the airway relevance of loci and genes identifed in GWAS studies. GWASs were searched from databases, and a list of loci associating signifcantly (p < 10–8) with asthma, AR and CRS was created. This yielded a total of 267 signifcantly asthma/AR–associated loci from 31 GWASs. No signifcant CRS ‑associated loci were found in this search. A total of 170 protein coding genes were connected to these loci. Of these, 76/170 (44%) showed bronchial epithelial protein expression in stained microscopic fgures of Human Protein Atlas (HPA), and 61/170 (36%) had a literature report of having airway epithelial function. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) annotation analyses were performed, and 19 functional protein categories were found as signif‑ cantly (p < 0.05) enriched among these genes. These were related to cytokine production, cell activation and adaptive immune response, and all were strongly connected in network analysis.
[Show full text]
Chromosome 14 Deletions, Rings, and Epilepsy Genes: a Riddle Wrapped in a Mystery Inside an Enigma
Received: 24 June 2020 | Revised: 16 October 2020 | Accepted: 16 October 2020 DOI: 10.1111/epi.16754 CRITICAL REVIEW – INVITED COMMENTARY Chromosome 14 deletions, rings, and epilepsy genes: A riddle wrapped in a mystery inside an enigma Alessandro Vaisfeld1 | Serena Spartano1 | Giuseppe Gobbi2 | Annamaria Vezzani3 | Giovanni Neri1,4 1Institute of Genomic Medicine, Catholic University School of Medicine, Rome, Italy Abstract 2Residential Center for Rehabilitation Luce The ring 14 syndrome is a rare condition caused by the rearrangement of one chromo- Sul Mare, Rimini, Italy some 14 into a ring-like structure. The formation of the ring requires two breakpoints 3 Department of Neuroscience, IRCCS- and loss of material from the short and long arms of the chromosome. Like many Istituto di Ricerche Farmacologiche Mario other chromosome syndromes, it is characterized by multiple congenital anomalies Negri, Milano, Italy 4J.C. Self Research Institute, Greenwood and developmental delays. Typical of the condition are retinal anomalies and drug- Genetic Center, Greenwood, SC, USA resistant epilepsy. These latter manifestations are not found in individuals who are carriers of comparable 14q deletions without formation of a ring (linear deletions). Correspondence Giovanni Neri, Institute of Genomic To find an explanation for this apparent discrepancy and gain insight into the mecha- Medicine, Catholic University School of nisms leading to seizures, we reviewed and compared literature cases of both ring Medicine, Rome, Italy. and linear deletion syndrome with respect to both their clinical manifestations and Email: [email protected] the role and function of potentially epileptogenic genes. Knowledge of the epilepsy- Funding information related genes in chromosome 14 is an important premise for the search of new and Ring 14 International; Ring14 Italia effective drugs to combat seizures.
[Show full text]